Search
for
Sort by
Research 121–150 of 1000+
- Clinical perspective on management of key adverse events with sacituzumab govitecan
- Data from A Phase Ib Study of Chemoimmunotherapy with Pegylated Liposomal Doxorubicin and Pembrolizumab in Estrogen Receptor–Positive Metastatic Breast Cancer
- A phase 1b study of chemo-immunotherapy with pegylated liposomal doxorubicin and Pembrolizumab in estrogen receptor positive metastatic breast cancer
- Oculoplastic Surgery Atlas. Eyelid Disorders: . Eds Geoffrey J Gladstone, Evan H Black, Shoib Myint, Brian G Brazzo. Pp 130; pound66.50. Heidelberg: Springer-Verlag, 2001. ISBN 0-387-95316-7.
- An enzyme-linked immunosorbent assay for detection of botulinum toxin antibodies
- Treatment of invasive aspergillosis with itraconazole
- Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer
- Bendamustine in Indolent Non-Hodgkin's Lymphoma: A Practice Guide for Patient Management
- Clinical Development of Topoisomerase-Interactive Drugs
- Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer
- Managing the adverse effects of cytotoxic chemotherapy at the level of primary healthcare
- Safety profile of CAP7.1 obtained during Phase I Trial in adult patients with refractory malignancies
- Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
- Chemotherapy for children with medulloblastoma
- Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda®)
- Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
- Role of liposomal anthracyclines in the treatment of multiple myeloma
- A phase I study of MK-5108, an oral aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors.
- Gemcitabine in combination with vinorelbine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer
- Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer
- Salvage Chemotherapy in Follicular Non-Hodgkin's Lymphoma: Focus on Tolerability
- Innovative sequence of docetaxel–gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study
- 2 SIDES OF LUPUS: CASE REPORT
- Non-pharmacological interventions for side effects of antineoplastic chemotherapy prioritized by patients: systematic review
- An Underrecognized Adverse Effect of Azithromycin
- Three Cases of Hemodialysis Patients with Advanced Gastric Cancer Treated with Paclitaxel and Nab Paclitaxel
- Dermatological drugs, topical agents, and cosmetics
- Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody–drug conjugate in breast cancer
- КЛІНІЧНІ ФЕНОТИПИ ВИСОКОГО РИЗИКУ НАЯВНОСТІ ПЕРВИННИХ МІТОХОНДРІАЛЬНИХ ЦИТОПАТІЙ (частина 2)
- Eribulin Effectiveness and Safety in Metastatic Triple-Negative Breast Cancer: A Narrative Review